Crossmark

Endotyping-informed therapy for patients with chest pain and no obstructive coronary artery disease: a randomized trial

Crossref DOI link: https://doi.org/10.1038/s41591-025-04044-4

Published Online: 2025-11-10

Published Print: 2026-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bradley, Conor P.

McKinley, Gemma

Orchard, Vanessa

Tiller, Christina

Stanley, Beth

Ang, Daniel

Morrow, Andrew J.

Sykes, Robert https://orcid.org/0000-0003-1010-5474
Gildea, Pamela https://orcid.org/0009-0000-8283-5113
Petty, Maria

Brogan, Richard https://orcid.org/0000-0003-2265-0488
Carrick, David

Collison, Damien

Eteiba, Hany

Ghattas, Angie

Good, Richard https://orcid.org/0000-0002-3906-1025
Joshi, Francis

Lindsay, Mitchell

McCartney, Peter

McGowan, James

McGeoch, Ross

Robertson, Keith https://orcid.org/0000-0002-6557-8298
Rocchiccioli, Paul

Shaukat, Aadil

Watkins, Stuart

Kellman, Peter

McConnachie, Alex https://orcid.org/0000-0002-7262-7000
Berry, Colin https://orcid.org/0000-0002-4547-8636
Funding

Funding for this research was provided by:

British Heart Foundation (PG/19/28/34310)

British Heart Foundation (PG/19/28/34310)

British Heart Foundation (PG/19/28/34310)

British Heart Foundation (PG/19/28/34310)

British Heart Foundation (PG/19/28/34310)
License Information

Text and Data Mining valid from 2025-11-10

Version of Record valid from 2025-11-10
More Information

Article History

Received: 25 August 2025

Accepted: 6 October 2025

First Online: 10 November 2025

Competing interests

: R.S. discloses International (WO) Patent Application No. PCT/EP2025/054222 for ‘Virtual Coronary Physiology’. D. Carrick has received consultancy fees and conference travel support from Philips and VP Med Group. D. Collison has received speaker/consultancy fees from Abbott and speaker fees/honoraria from GE Healthcare. F.J. received research funding from Boston Scientific and consultancy fees from Boston Scientific, Abbott Vascular and Shockwave Medical. S.W. has received consulting fees from Abbott Vascular. P.K. is a consultant for Siemens Healthcare. C.B. is employed by the University of Glasgow, which holds consultancy and research agreements for his work with Abbott Vascular, AskBio, AstraZeneca, Boehringer Ingelheim, CorFlow, Edwards Lifesciences, Merck, Servier, Novartis, Xylocor and Zoll Medical. None of the other authors has any potential conflicts of interest.

Document is current

Any future updates will be listed below